NCT00152126View on ClinicalTrials.gov

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

August 31, 2005

Study Completion Date

February 28, 2009

Conditions
NeuroblastomaCentral Nervous System TumorsLymphomasWilms Tumor
Interventions
PROCEDURE

Stem Cell Transplantation

Autologous stem cell transplantation

DRUG

Busulfan, Melphalan

Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
collaborator

University of Miami

OTHER

lead

St. Jude Children's Research Hospital

OTHER

NCT00152126 - Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas | Biotech Hunter | Biotech Hunter